Eisai reports degrowth for 3 consecutive years
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.07.23 05:40:25
가나다라
0
Sales in 2021,2022, 2023 draw a ‘downward slope,’ recording KRW 212.9 billion, KRW 140.4 billion, and KRW 139.3 billion, respectively
Sales of anticancer drug Lenvima fall from KRW 13.6 billion to KRW 10.3 billion…Boryung’s generic entry remains of concern for Eisai
New drug ‘Leqembi’ for Alzheimer’s and the JAK inhibitor ‘Jyseleca’ have the potential to raise company sales
Eisai Korea has recorded a decline in sales of its flagship products, including its anti-cancer drug Lenvima (lenvatinib), for 3 consecutive years since 2020.
The company has not seen a clear rebound since experiencing a significant drop in sales in 2022. The company’s JAK inhibitor Jyseleca (filgotinib), which was listed for reimbursement late last year, and the dementia drug Leqembi (lecanemab-irmb), which is expected to be launched by the end of the year, are gaining interest as potential drivers of the company’s performance growth.
▲렌비마 제품사진
Eisai’s sales last year recorded KRW139.3 billion... backsliding every year since 2021's KRW 221.9 billion
In 2023, Eisai
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)